SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Ask Vendit Off-Topic Questions
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Vendit™ who wrote (2661)12/15/2004 8:07:02 AM
From: Walkingshadow  Read Replies (1) of 8752
 
Reid, here's another risky one along the lines of NURO (note the volume!!) that is under my radar, and is coiling up nicely:

139.142.147.218

Some good news in the sector this morning. CHIR just got priority review status by the FDA for Pulminiq. So, for NRMX, today might be their day, and the start of a sweet little trip to the top rail of the BBs maybe?

========================================
Wells Fargo initiates Neurochem (NRMX) with a Buy and $27 target. The co focuses on the development of orally active drugs for neurological disorders and has two late-stage clinical products. Given that Alzhemed (for Alzheimer's disease) addresses a large market with broad, unmet medical needs if approved, it would have blockbuster potential. Currently in Phase III, Alzhemed could become the first in a new class of drugs for AD. While current treatments merely target symptoms of AD, Alzhemed is designed to address the underlying causes by modifying its progression. The firm forecasts Phase III data for Alzhemed in early 2007, a US launch in early 2008, and total peak annual sales of $2 bln. Upcoming milestones for Neurochem include: 1) initiation of a second Phase III trial for Alzhemed in 1Q05; 2) Fibrillex Phase II/III data in 2Q05; 3) NDA filing for Fibrillex in mid-2005; and 4) potential Fibrillex partnership in 1H05.

================================================
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News